Cardiac surgery patients are now more risky in terms of age, comorbidities, and the need for complex procedures. It brings about reperfusion injury, which leads to dysfunction and/or loss of part of the myocardium. These groups of patients have a higher incidence of postoperative complications and mortality. One factor to consider involves the current limits for perioperative myocardial protection [2, 3]. Some patients may be offered revascularisation on the beating heart, transcatheter implantation of heart valve prosthesis, or a mitral clip, but for the surgical field to be peaceful and bloodless, the majority of high-risk patients are operated on using the so-called ischaemic cardioplegic arrest. Here, the restoration of the coronary circulation is accompanied by acute ischaemia-reperfusion injury (IRI) with raised cardiac enzymes [4]. Some degree of cardiac necrosis is inherent in each cardiac surgery and, in addition to reperfusion injury, multiple heart/renal failure, cerebral stroke) and ultimately a higher mortality. One factor to consider involves the current limits for perioperative myocardial protection [2, 3]. Some patients may be offered revascularisation on the beating heart, transcatheter implantation of heart valve prosthesis, or a mitral clip, but for the surgical field to be peaceful and bloodless, the majority of high-risk patients are operated on using the so-called ischaemic cardioplegic arrest. Here, the restoration of the coronary circulation is accompanied by acute ischaemia-reperfusion injury (IRI) with raised cardiac enzymes [4]. Some degree of cardiac necrosis is inherent in each cardiac surgery and, in addition to reperfusion injury, multiple
factors may be involved [5]. According to recent studies, the incidence of myocardial infarction (MI) after CABG ranges, depending on the definition, from 2% to 10% [6]. According to the latest revised definition, MI arising in connection with CABG (“Category 5”) is arbitrarily determined by a 10-fold increase in cardiac-specific enzymes during the first 48 hours along with ECG signs of necrosis or displaying a coronary occlusion/contractility disorder [7, 8]. The term “perioperative myocardial injury” describes a condition that, although not fully achieving MI type 5, has health consequences even at this level of affection. A new retrospective study on 18,908 CABG patients has found that CK-MB/troponin elevations in the initial 24 hours were associated with increased mortality in the coming months to years [9]. Thus, it is obvious that the restriction of perioperative myocardial injury is important for the prognosis of the patient. The facts mentioned above open the door to finding other methods of perioperative myocardial protection in cardiac surgery.

2. Cardioplegia

The current gold standard of cardioplegia is a depolarisation myocardial arrest through perfusion of the coronary arteries using a hyperkalaemic solution. The time of reversible ischaemia that it provides is satisfactory for the surgery (up to 4 hours); plus, there is the restoration of function (a number of days) and low systemic toxicity [10]. Myocardial protection is expressed by delaying irreversible ischaemia, to which the arrest of electrical and mechanical activity is a contributing factor. The use of potassium, however, is not lacking in problems; in addition to the very narrow safety profile of extracellular potassium (10–30 mmol per litre), there is a calcium overload of the myocytes; plus, there are other types of ionic imbalance that lead to arrhythmias and depressed myocardial function persisting over several days [11]. Myocardial protection is reinforced using hypothermia, mixing the cardioplegic solution with the patient’s blood and a number of additives: procaine, adenosine (augmented attenuation of electrical activity), calcium antagonists, magnesium (inhibition of calcium overloading), desensitisation of calcium channels (inhibition of calcium at the myofilament level), energy substrate (anaerobic ATP production), mannitol, Fe chelates (oedematous and oxidation control effect), and others. Additives are not part of every cardioplegic solution, because they are accompanied by side effects [12]. An alternative to the hyperkalaemic depolarisation arrest is the hyperpolarisation arrest induced by decreasing sodium and calcium from solutions such as Bretschneider solution and its later version, Custodiol HTK (histidine-tryptophan-ketoglutarate solution), but even this approach does not lead to a qualitative change in myocardial protection from reperfusion injury [2]. Hyperpolarisation can also be induced by agents that open membrane potassium channels (outflow of potassium from myocytes). This leads to the reduction in the calcium influx into myocytes (by reducing the action potential) without having to add other agents with adverse effects. Studies with aprikalim, pinacidil, or nicorandil showed a comparable or better cardioprotection level but failed in clinical practice due to a long elimination time and systemic hypotension [13].

3. Reperfusion Injury (RI) of Myocardium

Myocardial RI is a complex response of the organism to the restoration of coronary blood flow in the ischaemic tissue and is an important component of ischaemia-reperfusion injury [14, 15]. The flow restoration rescues viable myocytes, accelerating the formation of necrosis of irreversibly damaged cells [16, 17]. In another portion of reperfused myocardium, there are subtle changes such as cell swelling, enlargement of mitochondria, or loss of myofibrillar organisation. The exposed area may recover or reach up to the death of cells, the morphological correlates of which are, at the tissue level and organ levels, referred to as contraction band necrosis [18] and the no-reflow phenomenon [19], respectively. This observation led to the concept of lethal reperfusion injury as early as 1985 [20]. RI is mostly manifest in reversible changes such as ventricular arrhythmias [21] and contractile dysfunctions (stunning) [22, 23]. The restoration of coronary flow after cardioplegic arrest is also manifest in disorders of rhythm and contractility, with contraction band necrosis possibly found in the myocardium. These were detected in 26% of early deaths of CABG patients, whilst also being found in almost all those with synchronous myocardial infarction as a result of graft occlusion [24].

Although the no-reflow phenomenon was described as early as 1966, the aetiology is still unclear. There are a number of other events involved, including embolisation of debris from the site of the occlusion, the release of vasoconstrictor and thrombogenic factors, and inflammatory substances; plus there are considerations in respect of the structural collapse of the capillary bed [25]. Whether RI is an independent factor responsible for additional tissue necrosis or simply speeds up exiting of cells condemned to death from ischaemia has been the subject of debates, the process being most intense in the 1990s [26], since it is difficult to discern the death of myocytes that were viable at the end of ischaemia. However, it is now accepted that RI is an independent factor for the spread of infarction after myocardial ischaemia [27]. The evidence is, nonetheless, only indirect, relying on the positive impact of therapeutic interventions at the reperfusion stage. Cardiac surgery has long been aware of the positive effect of the modified reperfusion (temperature and composition) and staged reperfusion (a slow, 20-minute restoration of coronary flow) [28, 29]. Mainly, the 36% reduction in infarction in STEMI patients treated with primary PCI and randomized to ischaemic postconditioning (see below [30]) is indirect evidence of this.

3.1. The RI Mechanisms. Oxygen is the main factor of damage, that is, its acute lack in the phase of ischaemia and toxicity in the reperfusion phase. This paradox can be explained by the evolution of the relationship between organisms and oxygen on Earth. After the increase in concentration of oxygen in the atmosphere 2.4 billion years ago that nearly wiped out life on Earth (the great oxygenation event), aerobic
organisms entered the path of adaptation, eventually ending up on oxygen, an electron acceptor for their energy mechanisms. Multicellular organisms thus gained the opportunity of explosive development at the cost of shortening the lifespan of individuals. Although widespread, the evolutionary young cellular mechanisms of protection against oxygen handling are not very robust. To this day, eukaryotic cells are dealing with a difficult logistical task, that is, to bring enough oxygen to the cell for respiration whilst eliminating the pernicious consequences of its presence. The start of reperfusion is the moment at which cells are most vulnerable, and as for antioxidant enzymes to regenerate, available energy is needed [31, 32].

The closure of the coronary artery leads to a series of changes, which begins with dysfunction and ends with myocardial infarction. The changes mainly concern the reduction of energy production and consumption. From the onset of ischaemia in myocytes, there is a sharp ongoing decline in ATP, with anaerobic utilisation of energy with a subsequent decrease in pH. Acidosis leads to contractility arrest within minutes, and complete depletion of ATP over 15–30 minutes results in myocyte death, at least as part of experiments. Intracellular acidosis is mitigated by a sodium-hydrogen pump; this taking place at the cost of intracellular entry of sodium, then water, and then even calcium. Deficient membrane ATPases are at the beginning of the disorder of the control of intracellular calcium, which leads to the first calcium overload. The hypothesis of ATP depletion being a central cause of ischaemic death still applies [33]; it was, however, extended by subsequent damage in the reperfusion phase. The restored oxygen supply and energy production in a situation of abnormal cellular environment leads to further damage [34]. Endogenous defence mechanisms are also activated in the early phase of reperfusion; these designed to minimize further damage to the myocardium; more specifically, there is a decision-making process as to which myocytes will be repaired or eliminated by apoptosis. Interconnected pathophysiological processes are supportive of RI, such as rapid pH fluctuations (pH paradox), oxygen toxicity (oxygen paradox), calcium overload of cells (calcium paradox), and inflammation [35]. Reperfusion promptly washes off the low pericellular pH with the emergence of a large H⁺ gradient on myocyte membranes. Activation of the Na/H pump follows, as well as the rapid entry of sodium into myocytes. This causes a passive reverse running of the membrane Na/Ca exchanger, the exchange of sodium for calcium causing the second intracellular calcium peak. The result of the rapid pH adjustment and calcium overload comprises an abolition of protease disinhibition (calpain, etc.), opening of mitochondrial transport channels (mPTP) and hypercontracture of the myofibrils (Figure 1). Reoxygenation starts aerobic ATP production, accompanied by explosive formation of the reactive oxygen species (ROS), the main sources of which involve calcium-activated xanthine oxidase and cytochrome of the respiratory chain. After overcoming the capacity of the main antioxidation enzymes SOD (superoxide dismutase) and catalase, the excess of ROS damages cell structures, especially membrane proteins and phospholipids. However, the initial amount of ROS during ischaemia alone and even at the beginning of reperfusion is necessary as a signal that activates defence mechanisms. These processes, along with the activation of inflammation cascades and bioactive factors such as cytokines, may lead to death of myocytes [36]. In the best case, the gradual regulation of ionic and electrophysiological processes in membranes is accompanied by arrhythmias and contractile dysfunction [37].

4. Myocardial Conditioning (MC)

One of the new ways of augmenting intraoperative myocardial protection is the activation of an innate defence mechanism to avoid reperfusion injury; one that was termed myocardial conditioning. Originally discovered in 1986 in the analysis of cumulative episodes of coronary occlusion and reperfusion, this principle was termed ischaemic preconditioning. Murry et al. described, on a canine model, a phenomenon in which four five-minute cycles of coronary occlusion and reperfusion prior to the sustained 40-minute occlusion reduce the extent of infarction by 25% [38]. This definition was further enhanced by the knowledge that ischaemic preconditioning also reduces dysrhythmias and myocardial dysfunction [39, 40]. The discovery was preceded by finding a warm-up phenomenon; patients with prodromal angina pectoris often show minor variations in the ST segment, less myocardial dysfunction, and an even lesser extent of necrosis [41]. Ischaemic preconditioning is underway in two stages, the early stage beginning immediately after ischaemia/reperfusion stimuli and lasting up to three hours, and is followed by a 12- to 24-hour interval after which there is the onset of the late stage; one that is weaker but lasts three days [42]. The early stage depends on the activation of available signalling molecules, receptors, and intracellular pathways, while the late stage requires the expression of defensive genes and de novo protein synthesis; see below. Myocardial conditioning evolved into multiple modalities that may be applied before (preconditioning), during (per-conditioning) and immediately after the ischaemic insult.

![Figure 1: Role of mitochondrial permeability transition pore (mPTP) in myocardial reperfusion injury.](image-url)
or at reperfusion (postconditioning). The stimulus can be applied directly to the myocardium or a remote tissue (remote conditioning).

### 4.1. Molecular Mechanisms of MC

Despite the accumulation of facts as regards the mechanism of inception, spreading, and implementation of the cardioprotective signal, there is now some sort of consensus as to the architecture of these; it can be divided into three levels (triggers, intracellular pathways, and end-effectors) [43]. Not only ischaemic, but also other types of stress (thermal, chemical), release triggers from the autocrine source (adenosine) or exogenous/paracrine sources (bradykinin, opioids). The triggers bind to receptors of the myocyte membrane, followed by a cascade activation of proteins/molecules of multiple parallel pathways, with this ending at the effector (mitochondria, cytoskeleton).

Intracellular signal transmission takes place via at least three parallel channels: the first is activated by receptors coupled with G protein (GPCR) and proceeds via a nitric oxide (NO), cGMP, and PKG (protein kinase G). The second channel, also activated by GPCR and termed RISK (reperfusion injury salvage kinase), contains a number of kinases including PKB (protein kinase B), ERK (extracellular regulated kinase) and key GSK 3beta (glucose synthase kinase). The third channel is SAFE (survival activating factor enhancement), which is activated by TNF-alpha and includes JAK (Janus kinase signal transducer) and STAT3 (mitochondrial activator of transcription).

Mitochondria are considered key effectors of cardioprotection, with mPTP (mitochondrial permeability transition pore) being the primary end point. They are nonspecific channels in the inner mitochondrial membrane, their physiological role being not known in detail [44]. Ischaemic stress opens mPTP, penetration of ions and water leads to swelling as far as rupture of the outer membrane, the release of proteins including cytochrome c, caspase activation, and apoptosis of the cell. Inhibition of GSK 3beta is an integration point of activation of protein kinase pathways, and, along with Connexin 43 and activation of potassium ATP channels (KAPT), “holds” mPTP in the closed state during the critical phase of reperfusion. Mitochondria are also a source of cardioprotective signal. At the start of reperfusion, it is necessary to produce a certain amount of reactive oxygen species that amplify protective mechanisms. Important factors also include the presence of acidosis, which is involved in the closure of mPTP and inhibits excessive contractile activity in the presence of excess calcium ions. The immediate reperfusion is thus a crucial moment when protective mechanisms (kinase signalling systems, ROS, acidosis) can be not only activated spontaneously or enhanced by the ischaemic pre/postconditioning, but also violated by inappropriate interventions, for example, incorrect timing of alkalisising substances and antioxidating agents. Figure 2 summarizes the molecular mechanisms of MC.

4.2. The Late Stage of Cardioprotection

The mechanisms of the acute and late stages of cardioprotection have many things in common. Some mediators of the intracellular signal transduction, however, induce gene transcription and synthesis of defensive proteins within 12–24 hours after the ischaemic stimulus [45]. These include transcription factors JAK-STAT 1/3 (Janus kinase/signal transducer and activator of transcription), PKC (protein kinase C), NF-kappa B (nuclear factor-kappa B), AP-1 (activator protein-1) and HIF-1 alpha (hypoxia inducible factor-1). This is followed by the synthesis of iNOS (induced nitric oxide synthases), Cox-2 (cyclooxygenase type 2), aldose reductase, mSOD (mitochondrial superoxide dismutase), and HSP (heat shock proteins). The products of these enzymes directly affect the mPTP as NO [46] and regulate the excessive production of ROS and aldehydes [47, 48]; plus, they protect the structure of proteins using HSP [49]. The detailed task of Cox-2 products (prostaglandins: PGE2, PGF1-alpha) is not yet known [50].

4.3. Ischaemic Postconditioning

Another modality which can reduce the size of myocardial infarction involves the application of several ischaemia–reperfusion stimuli immediately (within the first minute) after the restoration of perfusion in the ischaemic region [51]. The reduction in infarction was observed in all species of tested animals [52] and also in a clinical trial [30]. The mechanism is, in many respects, the same as for the standard modality, both of them sharing the necessity of the reperfusion stage, but here the SAFE kinase pathway dominates over RISK. While ischaemic preconditioning may be used only for elective procedures (percutaneous or surgical), postconditioning can be applied even to patients during primary percutaneous coronary interventions (PPCI).

4.4. Remote Ischaemic Conditioning: RIPC

Remote ischaemic conditioning is a form of cardioprotection induced by
short cycles of ischaemia and reperfusion, which are applied to a distant tissue and/or organ. The phenomenon was originally observed intraorganally and is interesting that it was predicted using a mathematical model [53]. In the original experiment, four cycles of five-minute occlusion–reperfusion in the circumflex branch of the left coronary artery led to a reduction of infarction in the area of ramus interventricularis anterior, which was subjected to 60-minute occlusion [54]. Subsequent studies showed that cardioprotection can be achieved even by applications to remote organs like kidney, intestine, brain, and skeletal muscle [55]. Remote pulses can be applied during an ongoing ischaemia (remote preconditioning), which can be advantageous prior to reception in STEMI patients [56] and also at the beginning of reperfusion (remote postconditioning) [57].

The mechanism of RIPC at the myocardial level is largely the same as in the basic application, but the transfer of the protective signal from a remote organ to the myocardium is not fully explained. Three channels of communication were designed and partially tested: the humoral blood channel, neuronal stimulation, and communication of immune cells. The humoral mechanism was tested by a perfusate and dialysate from the ischaemic organ, which induced cardioprotection after being applied to the isolated myocardium [58]. The identity of humoral factors also remains speculative. Classic triggers (bradykinin, opioids), but also as yet undefined small hydrophobic molecules, are considered [59]. Neuronal stimulation was verified by stimulation of the femoral nerve with the conclusion that intact neural pathways are required for the release of humoral components [60]. Other studies focused on parasympathetic activity, concluding that RIPC is dependent on the activity of specific vagal preganglionic neurons [61]. Not surprisingly, many assume the necessary interplay of these components [62].

Its noninvasiveness and ease of application determined RIPC to be the most tested modality in clinical research. In terms of orders, dozens of “proof of concept” clinical studies have tested remote conditioning by an application of ischaemia/reperfusion on the upper/lower limb using a pressure cuff in elective operations in cardiac surgery and invasive cardiology [63–71]. Nonetheless, not every study has confirmed cardioprotection [72–74].

Remote ischaemic conditioning (RIC) has regained interest in clinical testing. The first clinical trial was performed on a group of 37 children undergoing surgery for congenital heart defect. RIC stimulus comprised three five-minute inflations/deflations using a pressure cuff (200 mmHg) on the lower limb before connecting to extracorporeal circulation. Children randomized in the RIC group had a lower consumption of inotropes, lower inspiratory pressures, and lower serum troponin I concentrations for 24 hours after the surgery [78]. A series of similar studies followed, mainly in operations for CHD, but differences in the assessed parameters were not always found [72, 79, 80]. The reasons for the negative results could involve issues in transferring the experimental results into clinical practice in general (see below) and also differences in protocols (stimulus magnitude and timing), the selection of patients (age, comorbidities, and extent and type of operation), use of anaesthesia (IV versus inhaled anaesthetics), and others. A new meta-analysis of clinical studies on CABG patients, however, revealed that RIC reduced perioperative myocardial injury as measured by lower levels of serum troponin [81]. Currently ongoing large multicenter studies (ERICCA, RipHeart) are expected to resolve the issues [82].

Ischaemic postconditioning (IPostC) has been successfully tested in paediatric cardiac surgery. The IPostC stimulus comprised repeated 30-second aortic declamping and clamping before the definite myocardial reperfusion. Children randomized in the IPostC group had lower serum levels of CKMB and troponin T for two hours after the surgery [83]. Use in adults has the disadvantage of increased risk of thromboembolic complications in handling the aorta [84]. The children’s cardiac surgery also tested the remote application of the stimulus (remote ischaemic postconditioning, again with a lower release of troponin [85]), but again there was a failure of clinical effect in a study on 1,280 patients [86]. The authors themselves admitted that the propofol (a scavenger of oxygen radicals) that was used could void the cardioprotective effect of ischaemic preconditioning as demonstrated in previous studies [87]. IPostC was also clinically tested in invasive cardiology in primary percutaneous interventions, and, as already mentioned, the positive results of this study became indirect proof of the existence of reperfusion injury [30]. Checking of the usefulness in this indication is foreseen in the ongoing large multicenter studies. The initial results suggest that IPostC and other techniques benefit mainly STEMI patients with anterior localisation as well as a greater extent of affection [56].

Compared to the previous modalities, the late phase of ischaemic preconditioning was clinically tested only in two studies. Our research group conducted a study based on some negative studies in CABG patients. At the start of surgery or, more specifically, prior to the cardioplegic cardiac arrest itself, there are stress stimuli that may also activate the phenomenon of the early stage of ischaemic preconditioning (skin incision, sternotomy, and cardiopulmonary bypass) and the IC stimulus applied, local or remote, already comes as an extra event [88]. In addition, the early IC stage lasts a maximum of three hours, which does not even cover the period of surgery, not to mention the initial hours.

5. Clinical Studies

The basic type, ischaemic preconditioning (IPC), was first used in clinical testing on a small set of CABG patients in 1993, the stimulus comprising repeated aortic clamping and declamping prior to the cardioplegic arrest itself. The IPC group was observed to have an increased level of ATP in biopsies sampled and lower levels of serum troponin I [75, 76]. Meta-analysis of 22 similar studies (937 patients) found fewer arrhythmias, a lower consumption of inotropes, and shorter stay in the ICU in the IPC group, but these were not the main parameters assessed [77]. This basic technique was, however, not developed any further due to its invasive nature (risk of thromboembolism in the handling of the aorta) and the need for extended surgery time.
after the surgery, when there is the highest frequency of complications. In contrast, the late IC stage takes up to three days and offers protection from adverse events even in the early postoperative period. Our study was conducted on 60 CABG patients, the remote IC stimulus comprising three five-minute inflations/deflations using a pressure cuff applied to the upper limb 18 hours before the operation itself. Patients randomized in the L-RIPC group had a significantly lower serum level of troponin I in the eight hours after surgery [66]. While the second study published so far and conducted in children did not find differences in serum levels of troponin I, the L-RIPC group had lower levels of NT-BNP (N terminal pro-B-type natriuretic peptide) [89].

6. Pharmacological Cardioprotection

Revelation of the principles of ischaemia-reperfusion myocardial injury, on the one hand, and congenital defence mechanisms, on the other hand, offers the possibility of pharmacological intervention. Cardioprotective agents may be applied before application of the aortic clamp, added to the cardioplegic solution, or used in the reperfusion stage, or a combination of these may be an option. Just as with STEMI patients, drug administration may be considered during the acute myocardial ischaemia or in the reperfusion stage. The experiment successfully tested many substances and processes, clinical testing reducing the number of positive ones, and the most promising are now being tested in large sets of patients in multicenter studies. Recently, drugs are being tested (and attracting great attention) that mimic ischaemic conditioning (IC), at all of the three hierarchical levels, adenosine being amongst the first of such pharmaceuticals, the substance ranking among the IC triggers. For CABG patients, the administration of adenosine (intravenously or as part of cardioplegia) was associated with less myocardial injury and faster postoperative recovery [90, 91]; other studies were less conclusive [92, 93] and any further testing in cardiac surgery was paused due to hypertensive side effects. Similar side effects were exhibited by bradykinin [94]. Our research group tested tramadol on CABG patients, an opioid that also shows the serotonin effect, for which cardioprotective effects were demonstrated as well [95, 96]. Conversely, however, in this study tramadol increased postoperative serum levels of troponin I quite significantly. The explanation lies in a possible paradoxical serotonin response in patients with coronary artery disease. Serotonin dilates normal coronary arteries, while in atherosclerotic arteries it causes vasoconstriction [97]. Another substance that activates intracellular defensive pathways is atrial natriuretic peptide. Infusion of carperitide, the synthetic analogue, when started after primary PCI reduced infarction size in STEMI patients, as measured by lower levels of cardiac enzymes (15% reduction) and maintaining systolic function measured by EFLK [98]. Exenatide, a new antidiabetic drug with cardioprotective properties, appears to be more promising because it has demonstrated efficiency even over longer follow-up periods. The infusion of exenatide initiated 15 minutes prior to primary PCI in STEMI patients decreased infarction size by 23% as documented using CMRI (cardiac magnetic resonance imaging) 90 days after the intervention [99]. Inhaled anesthetics are a group of agents which have shown cardioprotective effects by influencing multiple hierarchical pathways. Meta-analysis of 27 clinical trials in CABG patients described in the sevoflurane group a lower release of troponin, less inotropic support, and preserved ventricular function [100]. Sevoflurane testing is now underway in acute cardiology in STEMI patients subjected to reperfusion (SIAM trial: In terms of mechanism of action, great attention is paid to cyclosporine A, which inhibits opening of MPTP channels in the mitochondria in the post-ischaemia reperfusion stage). Complex beneficial effects of nitric oxide donors in cardioprotection were described, which may be summarized in three points: (1) a direct haemodynamic effect mediated through vasodilation of coronary arteries, (2) a direct effect on improving cardiac output, and (3) an increase in vascular sensitivity to sympathetic stimulation could lead to increased diastolic blood pressure [101]. NO can also directly modify sulfhydryl residues of proteins through S-nitrosylation, which has emerged as an important posttranslational protein modification. S-nitrosylation of critical protein thiols has been shown to protect them from further oxidative modification by reactive oxygen species. Recently it has been suggested that S-Nitrosylation could play important role in cardioprotection [102]. Cyclosporine thus intervenes at the end-effector, where the defensive signals of intracellular pathways converge. A small clinical study on 27 STEMI patients treated by PPCI demonstrated in the cyclosporine group a 20% reduction in infarction on CMRI [103]. This and another study, which observed a lasting effect even after six months on the CMRI, gave rise to a wider study of CIRCUS trial: NCT01502774, which is now underway [104]. Other more specific inhibitors of MPTP channels are now being tested in ongoing trials (MITOCARE: NCT01374321, EMBRACE: NCT01572909) [105, 106]. Further interventions and pharmaceuticals that appeared to be efficient in animal models are being tested in acute cardiology: mesacermín, insulin-like growth factor analogue (RESUS-AMI: NCT01438086) [107], mangafodipir, iron oxidation inhibitor and chelator (MANAMI: NCT00966563) [108], melatonin (MARIA: NCT00640094) [109], inhaled nitric oxide (NOMI: NCT01398384) [110], IV sodium nitrite (NIAMI: NCT01388504) [111], intracoronary sodium nitrite (NITRITE-AMI: NCT01584453) [112], thymosin beta-4, growth regulator (NCT00378352) [113], and metoprolol (METOCARD-CNIC: NCT01311700) [114]. Those ongoing studies are summarized in Table 1. On the other hand, a number of pharmaceuticals proved inefficient in laboratory trials. In CABG patients, failure was found in cariporide, sodium-hydrogen exchanger inhibitor (GUARDIAN and EXPEDITION trials) [115, 116], acadesine, adenosine precursor (RED-CABG trial) [117], pexelizumab and C5 complement inhibitor (PRIMO-CABG trial) [118], while in STEMI patients failure was found in trimetazidine, fatty acid oxidation inhibition (EMIP-FR 2000 trial) [119], eniporid, sodium-hydrogen exchanger inhibitor (ESCAMI trial) [120], delcaxisertib, protein kinase C inhibitor
7. Challenges and Perspectives in Translation to Clinical Outcomes

The above studies represent only a small part of the efforts and resources that have been expended in this field. In the US alone, it is estimated that over the last 40 years, hundreds of millions of dollars were spent in preclinical studies for so-called infarction life-saving therapies. This gave rise to hundreds of treatments that were identified as controlling myocardial infarct size in animal models by mitigating reperfusion injury. On the other hand in the human FIRE Trial, FX06 reduced the necrotic core zone as one measure of infarct size on magnetic resonance imaging, while total late enhancement was not significantly different between groups [127].

(PROTECTION-AMI) [121], atorvastatin (REPARATOR trial) [122], and also magnesium (MAGIC trial) [123] and glucose-insulin-potassium infusion (CREATE-ECLA) [124]. According to the results of the REVEAL study, in patients with STEMI who had successful reperfusion with primary or rescue PCI, a single intravenous bolus of epoetin alfa within four hours of PCI did not reduce infarct size and was associated with higher rates of adverse cardiovascular events [125]. Moreover, erythropoietin may increase clinical adverse events [125, 126]. FX06, a naturally occurring peptide derived from human fibrin, has been shown to reduce myocardial infarct size in animal models by mitigating reperfusion injury. On the other hand in the human FIRE Trial, FX06 reduced the necrotic core zone as one measure of infarct size on magnetic resonance imaging, while total late enhancement was not significantly different between groups [127].

In 2003, a workshop took place in the US, initiated by NHLBI (National Heart, Lung, and Blood Institute), the event’s title, “Transfer of Therapies to Protect the Myocardium from Ischemia,” was self-explanatory and its main recommendations included continuation of the clinical testing of adenosine [150]. The AMISTAT 2 trial of 2005 compared infarction size in STEMI patients treated with PPCI with three-hour infusion of adenosine with dual concentration: 50 and 70 μg/kg/minute versus placebo. SPECT (single photon emission CT) revealed the smallest infarction in higher concentrations: 11%, 23% versus 27% for placebo [131]. However, the second NHLBI workshop in 2010 still identified a number of gaps existing in the knowledge of the key moments of acute reperfusion injury and defensive response of the organism. The mechanism of lethal reperfusion injury, as well as its possible influence, is still not explained. The same applies to the exact mechanism of microvascular obstruction (no-reflow phenomenon). There is also no determination regarding which cardioprotective therapy may be appropriate in which clinical situations. The so-called combination therapies, which could strengthen the efficiency of individual measures, were not tested to a great extent. As cardioprotective therapies fail in the patients who need them most, that is, older persons and persons with comorbidities (diabetes, hypertension, and dyslipoproteinaemia), it will therefore be necessary to find procedures that work especially in this regard. Finally, there is the necessity of identifying molecular markers that would indicate the presence of the cardioprotective state [132]. Challenges prevail over resolved issues; preclinical studies are, however, a good start. In 2011, the NHLBI awarded a five-year grant to the initiative called the Consortium for Preclinical Assessment of Cardioprotective Therapies (CAESAR), which will test promising cardioprotective therapies through the application of standard and randomized protocols carried out by blinded researchers and analysed by blinded analysis, as with clinical studies. The main aim of this consortium is to...
ensure repeatability of the results on relevant animal models, including conscious animals and comorbid models [133]. Optimism prevails in Europe as well. In 2013, a working group for cell biology of the heart, attached to the European Society of Cardiology, published a document entitled “Transferring Cardioprotection for the Benefit of the Patient,” its main proposition comprising the belief that the failure was in the inability successfully to transfer promising therapies into procedures that improve clinical outcomes, rather than in a lack of potential cardioprotective therapies in preclinical research [134].

8. Conclusion

The fundamental discovery of cardioplegic myocardial protection in cardiac surgery in the 1970s and 1980s enabled effective surgical treatment bringing prolonged and better-quality life to the patient. Also, early reperfusion in STEMI patients remains the only effective treatment in cardiology. Both therapeutic strategies, however, are accompanied by reperfusion injury of the myocardium, which leads to dysfunction and/or loss of part of the myocardium. During the same period, another fundamental discovery was made: termed ischemic preconditioning, it activates protection from ischaemia-reperfusion myocardial injury. The extensive research on this phenomenon in the past three decades has revealed basic mechanisms and suggested methods of use. Thus, the question is whether activation or augmentation of the defence mechanism may enhance myocardial protection in cardiac surgery or rescue another portion of the jeopardised myocardium after reperfusion therapy in STEMI patients. Although widespread, the evolutionary young cellular mechanisms of protection against oxygen handling are not very robust. Ischaemic conditioning, which is among them, is also thus limited and for myocardium, the organ with the highest oxygen turnover, it is of undeniable importance. At present, the prevailing belief is that such options of treatment exist for reperfusion myocardial injury, but the time for their full employment has not yet come, due to unresolved subquestions and methodological issues with the transfer into clinical practice.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgment

This work was supported by Grant of European Regional Development Fund—Project FNUSA-ICRC (no. CZ.1.05/1.1.00/02.0123).

References

[1] D. P. Taggart, S. Kaul, W. E. Boden et al., “Revascularization for unprotected left main stem coronary artery stenosis, stenting or surgery,” Journal of the American College of Cardiology, vol. 51, no. 9, pp. 885–892, 2008.

[2] M. L. Lima, A. I. Fiorelli, D. V. Vassallo, B. B. Pinheiro, N. A. G. Stolf, and O. M. Gomes, “Comparative experimental study of myocardial protection with crystalloid solutions for heart transplantation,” Brazilian Journal of Cardiovascular Surgery, vol. 27, no. 1, pp. 110–116, 2012.

[3] J. E. Flack III, J. R. Cook, S. J. May et al., “Does cardioplegia type affect outcome and survival in patients with advanced left ventricular dysfunction? Results from the CABG Patch Trial,” Circulation, vol. 102, no. 19, pp. II184–II189, 2000.

[4] F. Beyersdorf, Ischemia-Reperfusion Injury in Cardiac Surgery, Eurekah.com/Landes Bioscience, Austin, Tex, USA, 2001.

[5] M. A. Costa, R. G. Carere, S. V. Lichtenstein et al., “Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS),” Circulation, vol. 104, no. 22, pp. 2689–2693, 2001.

[6] K. Thygesen, J. S. Alpert, and H. D. White, “Universal definition of myocardial infarction,” Circulation, vol. 116, no. 22, pp. 2634–2653, 2007.

[7] K. Thygesen, J. S. Alpert, A. S. Jaffe, M. L. Simoons, B. R. Chaitman, and H. D. White, “Third universal definition of myocardial infarction,” Journal of the American College of Cardiology, vol. 60, no. 16, pp. 1581–1598, 2012.

[8] D. J. Hausenloy, E. Boston-Griffiths, and D. M. Yellon, “Cardioprotection during cardiac surgery,” Cardiovascular Research, vol. 94, no. 2, pp. 253–265, 2012.

[9] M. J. Domanski, K. Maahaffey, V. Hasselblad et al., “Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery,” Journal of the American Medical Association, vol. 305, no. 6, pp. 585–591, 2011.

[10] G. D. Buscberg, “Myocardial protection: an overview,” Seminars in Thoracic and Cardiovascular Surgery, vol. 5, pp. 98–106, 1993.

[11] D. J. Chambers and D. J. Hearse, “Cardioplegia and surgical ischemia,” in Heart Physiology and Pathophysiology, N. Spertelakis, Z. Kurachi, A. Terzic, and M. V. Cohen, Eds., Academic Press, San Diego, Calif, USA, 2001.

[12] A. Chambers, H. Fallouh, C. J. Kentish, and D. J. Chambers, “Cardioplegia by polarised arrest: experimental studies with potential for clinical application,” European Journal of Heart Failure, Supplement, vol. 8, no. 2, p. 256, 2009.

[13] D. J. Chambers and H. B. Fallouh, “Cardioplegia and cardiac surgery: pharmacological arrest and cardioprotection during global ischemia and reperfusion,” Pharmacology and Therapeutics, vol. 127, no. 1, pp. 41–52, 2010.

[14] R. B. Jennings, H. B. Sommers, A. M. Smyth, H. A. Flack, and H. Linn, “Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog,” Archives of Pathology, vol. 70, pp. 68–78, 1960.

[15] J. P. Monassier, V. Gressin, Y. Louvard, M. Hansen, J. Levy, and O. Katz, “The myocardial reperfusion syndrome,” Archives des Maladies du Coeur et des Vaisseaux, vol. 85, no. 5, pp. 743–750, 1992.

[16] R. B. Jennings, C. E. Murry, C. Steenbergen Jr., and K. A. Reimer, “Development of cell injury in sustained acute ischemia,” Circulation, vol. 82, no. 3, supplement, pp. II2–II12, 1990.

[17] K. A. Reimer, J. E. Lowe, M. M. Rasmussen, and R. B. Jennings, “The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs,” Circulation, vol. 56, no. 5, pp. 786–794, 1977.

[18] Y. Naka, D. M. Stern, and D. J. Pinski, “The pathophysiology and biochemistry of myocardial ischemia, necrosis, and reperfusion,” in Atherosclerosis and Coronary Artery Disease, V. Fuster,
R. Ross, and E. J. Topol, Eds., pp. 807–814, Lippincott - Raven, Philadelphia, Pa, USA, 1996.

[19] A. Krug, D. R. Du Mesnil, and G. Korb, "Blood supply of the myocardium after temporary coronary occlusion," Circulation Research, vol. 19, no. 1, pp. 57–62, 1966.

[20] E. Braunwald and R. A. Kloner, "Myocardial reperfusion: a double-edged sword?" Journal of Clinical Investigation, vol. 76, no. 5, pp. 1713–1719, 1985.

[21] A. S. Manning and D. J. Herse, "Reperfusion-induced arrhythmias: mechanism and prevention," Journal of Molecular and Cellular Cardiology, vol. 16, pp. 497–418, 1984.

[22] E. Braunwald and R. A. Kloner, "The stunned myocardium: prolonged, postischemic ventricular dysfunction," Circulation, vol. 66, no. 6, pp. 1146–1149, 1982.

[23] R. Bolli and E. Marbán, "Molecular and cellular mechanisms of myocardial stunning," Physiological Reviews, vol. 79, no. 2, pp. 609–634, 1999.

[24] S. M. Weman, P. J. Karhunen, A. Penttilä, A. A. Järvinen, and U.-S. Salminen, "Reperfusion injury associated with one-fourth of deaths after coronary artery bypass grafting," The Annals of Thoracic Surgery, vol. 70, no. 3, pp. 807–812, 2000.

[25] G. M. Fröhlich, P. Meier, S. K. White, D. M. Yellon, and D. J. Hausenloy, "Myocardial reperfusion injury: looking beyond primary PCI," European Heart Journal, vol. 34, no. 23, pp. 1714–1724, 2013.

[26] R. A. Kloner, "Does reperfusion injury exist in humans?" Journal of the American College of Cardiology, vol. 21, no. 2, pp. 537–545, 1993.

[27] D. M. Yellon and D. J. Hausenloy, "Myocardial reperfusion injury," The New England Journal of Medicine, vol. 357, no. 11, pp. 1074–1135, 2007.

[28] M. Hori, M. Kitakaze, H. Sato et al., "Staged reperfusion attenuates myocardial stunning in dogs. Role of transient acidosis during early reperfusion," Circulation, vol. 84, no. 5, pp. 2135–2145, 1991.

[29] G. Heusch, "Postconditioning: old wine in a new bottle?" Journal of the American College of Cardiology, vol. 44, no. 5, pp. 1111–1122, 2004.

[30] P. Staats, G. Rioufol, C. Piot et al., "Postconditioning the human heart," Circulation, vol. 112, no. 14, pp. 2143–2148, 2005.

[31] F. J. Giordano, "Oxygen, oxidative stress, hypoxia, and heart failure," Journal of Clinical Investigation, vol. 115, no. 5, pp. 500–508, 2005.

[32] K. J. Davies, "Oxidative stress: the paradox of aerobic life," Biochemical Society Symposium, vol. 61, pp. 1–31, 1995.

[33] D. G. Allen and C. H. Orchard, "Myocardial contractile function during ischemia and hypoxia," Circulation Research, vol. 60, no. 2, pp. 153–168, 1987.

[34] D. J. Hease, S. M. Humphrey, and E. B. Chain, "Abrupt reoxygenation of the anoxic potassium arrested perfused rat heart: a study of myocardial enzyme release," Journal of Molecular and Cellular Cardiology, vol. 5, no. 4, pp. 395–407, 1973.

[35] D. M. Yellon and D. J. Hausenloy, "Myocardial reperfusion injury," The New England Journal of Medicine, vol. 357, no. 11, pp. 1121–1135, 2007.

[36] Á. B. Gustafsson and R. A. Gottlieb, "Heart mitochondria: gates of life and death," Cardiovascular Research, vol. 77, no. 2, pp. 334–343, 2008.

[37] S. Sanada, I. Komuro, and M. Kitakaze, "Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures," American Journal of Physiology: Heart and Circulatory Physiology, vol. 301, no. 5, pp. H1723–H1741, 2011.

[38] C. E. Murry, R. B. Jennings, and K. A. Reimer, "Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium," Circulation, vol. 74, no. 5, pp. 1124–1136, 1986.

[39] K. Shihi and D. I. Heares, "Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias," The American Journal of Physiology, vol. 253, pp. H1470–H1476, 1987.

[40] G. K. Asimakis, K. Innens-McBride, G. Medellin, and V. R. Conti, "Ischemic preconditioning attenuates acidosis and postischemic dysfunction in isolated rat heart," The American Journal of Physiology—Heart and Circulatory Physiology, vol. 263, no. 3, pp. H887–H894, 1992.

[41] M. D. Jaffe and N. K. Quinn, "Warm-up phenomenon in angina pectoris," The Lancet, vol. 2, no. 8201, pp. 934–936, 1980.

[42] M. S. Marber, D. S. Latchman, J. M. Walker, and D. M. Yellon, "Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction," Circulation, vol. 88, no. 3, pp. 1264–1272, 1993.

[43] G. Keusch, K. Boengler, and R. Schulz, "Cardioprotection: nitric oxide, protein kinases, and mitochondria," Circulation, vol. 118, no. 19, pp. 1915–1919, 2008.

[44] D. J. Hausenloy, H. L. Maddock, G. F. Baxter, and D. M. Yellon, "Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?" Cardiovascular Research, vol. 55, no. 3, pp. 534–543, 2002.

[45] R. Bolli, "The late phase of preconditioning," Circulation Research, vol. 87, no. 11, pp. 972–983, 2000.

[46] M. B. West, G. Rokosh, D. Obal et al., "Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition," Circulation, vol. 118, no. 19, pp. 1970–1978, 2008.

[47] N. Yamashita, M. Nishida, S. Hoshida et al., "Induction of manganese superoxide dismutase in rat cardiac myocytes increases tolerance to hypoxia 24 hours after preconditioning," Journal of Clinical Investigation, vol. 94, no. 6, pp. 2193–2199, 1994.

[48] K. Shimamura, R. Bolli, S. Q. Liu et al., "Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning," Circulation Research, vol. 91, no. 3, pp. 240–246, 2002.

[49] J. Zhou, J. Pei, G. Wang et al., "Inducible HSP70 mediates delayed cardioprotection via U-50488H pretreatment in rat ventricular myocytes," American Journal of Physiology-Heart and Circulatory Physiology, vol. 281, no. 1, pp. H40–H47, 2001.

[50] H. H. Patel, A. K. Hsu, and G. J. Gross, "COX-2 and iNOS in dialysis injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning," The American Journal of Physiology—Heart and Circulatory Physiology, vol. 285, no. 2, pp. H579–H588, 2003.

[51] Z. Zhao, J. S. Corvera, M. E. Halkos et al., "Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning," The American Journal of Physiology—Heart and Circulatory Physiology, vol. 285, no. 2, pp. H579–H588, 2003.
[54] K. Przyklenk, B. Bauer, M. Ovize, R. A. Klomer, and P. Whittaker, “Regional ischemic pre-conditioning protects remote virgin myocardium from subsequent sustained coronary occlusion,” Circulation, vol. 87, no. 3, pp. 893–899, 1993.

[55] R. K. Kharbanda, U. M. Mortensen, P. A. White et al., “Transient limb ischemia induces remote ischemic preconditioning in vivo,” Circulation, vol. 106, no. 23, pp. 2881–2883, 2002.

[56] H. E. Bøtker, R. Kharbanda, M. R. Schmidt et al., “Remote ischemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial,” The Lancet, vol. 375, no. 9716, pp. 727–734, 2010.

[57] G. Andreka, M. Vertesaljai, G. Szantho et al., “Remote ischemic postconditioning protects the heart during acute myocardial infarction in pigs,” Heart, vol. 93, no. 6, pp. 749–752, 2007.

[58] L. Breivik, E. Helgeland, E. K. Aarnes, J. Mrdalj, and A. K. Jonassen, “Remote postconditioning by humoral factors in effluent from ischemic preconditioned rat hearts is mediated via PI3K/Akt-dependent cell-survival signaling at reperfusion,” Basic Research in Cardiology, vol. 106, no. 1, pp. 135–145, 2011.

[59] M. Shimizu, M. Tropak, R. J. Diaz et al., “Transient limb ischemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection,” Clinical Science, vol. 117, no. 5, pp. 191–200, 2009.

[60] T. Steensrud, J. Li, X. Dai et al., “Pretreatment with the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote limb ischemia or intra-arterial adenosine,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 299, no. 5, pp. H1598–H1603, 2010.

[61] S. Mastitskaya, N. Marina, A. Gourine et al., “Cardioprotection evoked by remote ischemic preconditioning is critically dependent on the activity of vagal pre-ganglionic neurones,” Cardiovascular Research, vol. 95, no. 4, pp. 487–494, 2012.

[62] S. Y. Lim, D. M. Yellon, and D. J. Hausenloy, “The neural and humoral pathways in remote limb ischemic preconditioning,” Basic Research in Cardiology, vol. 105, no. 5, pp. 651–655, 2010.

[63] D. J. Hausenloy, P. K. Mwamure, V. Venugopal et al., “Effect of remote ischemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial,” The Lancet, vol. 370, no. 9587, pp. 575–579, 2007.

[64] N. Ali, F. Rizwi, A. Iqbal, and A. Rashid, “Induced remote ischemic pre-conditioning on ischemia-reperfusion injury in patients undergoing coronary artery bypass,” Journal of the College of Physicians and Surgeons Pakistan, vol. 20, no. 7, pp. 427–431, 2010.

[65] D. M. Hong, J. J. Min, J. H. Kim et al., “The effect of remote ischemic preconditioning on myocardial injury in patients undergoing off-pump coronary artery bypass graft surgery,” Anaesthesia and Intensive Care, vol. 38, no. 5, pp. 924–929, 2010.

[66] R. Wagner, P. Piler, H. Bedanova, P. Adamek, L. Grodecka, and T. Freiberger, “Myocardial injury is decreased by late remote ischemic preconditioning and aggravated by tramadol in patients undergoing cardiac surgery: a randomised controlled trial,” Interactive Cardiovascular and Thoracic Surgery, vol. 11, no. 6, pp. 758–762, 2010.

[67] Q. Wu, P. Gui, J. Wu et al., “Effect of limb ischemic preconditioning on myocardial injury in patients undergoing mitral valve replacement surgery: a randomized controlled trial,” Circulation Journal, vol. 75, no. 8, pp. 1885–1889, 2011.

[68] J. J. Xie, X. L. Liao, W. G. Chen et al., “Remote ischemic pre-conditioning reduces myocardial injury in patients undergoing heart valve surgery: randomised controlled trial,” Heart, vol. 98, no. 5, pp. 384–388, 2012.

[69] S. P. Hooie, P. M. Heck, L. Sharples et al., “Cardiac remote ischemic preconditioning in coronary stenting (CRISP stent) study: a prospective, randomized control trial,” Circulation, vol. 119, no. 6, pp. 820–827, 2009.

[70] K. Munk, N. H. Andersen, M. R. Schmidt et al., “Remote ischemic conditioning in patients with myocardial infarction treated with primary angioplasty: impact on left ventricular function assessed by comprehensive echocardiography and gated single-photon emission CT,” Circulation: Cardiovascular Imaging, vol. 3, no. 6, pp. 656–662, 2010.

[71] I. Rentoukas, G. Giannopoulos, A. Kaoukis et al., “Cardioprotective role of remote ischemic perconditioning in primary percutaneous coronary intervention,” JACC: Cardiovascular Interventions, vol. 3, no. 1, pp. 49–55, 2010.

[72] I. A. Rahman, J. G. Mascaro, R. P. Steeds et al., “Remote ischemic preconditioning in human coronary artery bypass surgery: from promise to disappointment?” Circulation, vol. 122, no. 11, pp. S53–S59, 2010.

[73] E. Lucchini, L. Bestmann, J. Feng et al., “Remote ischemic preconditioning applied during isoflurane inhalation provides no benefit to the myocardium of patients undergoing on-pump coronary artery bypass graft surgery: lack of synergy or evidence of antagonism in cardioprotection?” Anesthesiology, vol. 116, no. 2, pp. 296–310, 2012.

[74] P. J. Young, P. Dalley, A. Garden et al., “A pilot study investigating the effects of remote ischemic preconditioning in high-risk cardiac surgery using a randomized controlled double-blind protocol,” Basic Research in Cardiology, vol. 107, no. 3, article 0256, 2012.

[75] D. M. Yellon, A. M. Alkhulaifi, and W. B. Pugsley, “Preconditioning the human myocardium,” The Lancet, vol. 342, no. 8866, pp. 276–277, 1993.

[76] D. P. Jenkins, W. B. Pugsley, A. M. Alkhulaifi, M. Kemp, J. Hooper, and D. M. Yellon, “Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery,” Heart, vol. 77, no. 4, pp. 314–318, 1997.

[77] S. R. Walsh, T. Y. Tang, P. Kullar, D. P. Jenkins, D. P. Dutka, and M. E. Gaunt, “Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials,” European Journal of Cardio-thoracic Surgery, vol. 34, no. 5, pp. 985–994, 2008.

[78] M. M. H. Cheung, R. K. Kharbanda, I. E. Konstantinov et al., “Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans,” Journal of the American College of Cardiology, vol. 47, no. 11, pp. 2277–2282, 2006.

[79] M. Thielmann, E. Kottenberg, K. Boengler et al., “Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest,” Basic Research in Cardiology, vol. 105, no. 5, pp. 657–664, 2010.

[80] P. Karuppasamy, S. Chaubey, T. Dew et al., “Remote intermittent ischemia before coronary artery bypass graft surgery: a strategy to reduce injury and inflammation?” Basic Research in Cardiology, vol. 106, no. 4, pp. 511–519, 2011.

[81] F. D’Ascenzo, E. Cavallero, C. Moretti et al., “Remote ischemic preconditioning in coronary artery bypass surgery: a meta-analysis,” Heart, vol. 98, no. 17, pp. 1267–1271, 2012.
[82] D. J. Hausenloy, L. Candilio, C. Laing et al., “Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial,” *Clinical Research in Cardiology*, vol. 101, no. 5, pp. 339–348, 2012.

[83] W. Luo, B. Li, G. Lin, and R. Huang, “Postconditioning in cardiac surgery for tetralogy of Fallot,” *The Journal of Thoracic and Cardiovascular Surgery*, vol. 133, no. 5, pp. 1373–1374, 2007.

[84] W. Luo, B. Li, R. Chen, R. Huang, and G. Lin, “Effect of ischemic postconditioning in adult valve replacement,” *European Journal of Cardio-thoracic Surgery*, vol. 33, no. 2, pp. 203–208, 2008.

[85] H. Zhong, Z. Gao, M. Chen et al., “Cardioprotective effect of remote ischemic postconditioning on children undergoing cardiac surgery: a randomized controlled trial,” *Paediatric Anaesthesia*, vol. 23, no. 8, pp. 726–733, 2013.

[86] D. M. Hong, E.-H. Lee, H. J. Kim et al., “Does remote ischaemic preconditioning with postconditioning improve clinical outcomes of patients undergoing cardiac surgery? Remote Ischaemic Preconditioning with Postconditioning Outcome Trial,” *European Heart Journal*, vol. 35, no. 3, pp. 176–183, 2013.

[87] E. Kottenberg, M. Thielmann, L. Bergmann et al., “Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol—a clinical trial,” *Acta Anaesthesiologica Scandinavica*, vol. 56, no. 1, pp. 30–38, 2012.

[88] P. G. Burns, I. B. Krukenkamp, C. A. Caldarone, G. R. Gaudette, E. A. Bukhari, and S. Levitsky, “Does cardiopulmonary bypass alone elicit myoventricular preconditioning?” *Circulation*, vol. 92, no. 9, pp. I1447–I1451, 1995.

[89] M. A. Pavione, F. Carmona, M. De Castro, and A. P. C. P. Carlotti, “Late remote ischemic preconditioning in children undergoing cardiopulmonary bypass: a randomized controlled trial,” *Journal of Thoracic and Cardiovascular Surgery*, vol. 144, no. 1, pp. 178–e1, 2012.

[90] H. T. Lee, R. J. LaFaro, and G. E. Reed, “Pretreatment of human myocardium with adenosine during open heart surgery,” *Journal of Cardiac Surgery*, vol. 10, no. 6, pp. 665–676, 1995.

[91] R. M. Mentzer Jr., P. S. Rahko, V. Molina-Viamonte et al., “Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during corona, artery bypass surgery,” *American Journal of Cardiology*, vol. 79, no. 12, pp. 38–43, 1997.

[92] D. Belhomme, J. Peynet, E. Florens, O. Tibourtine, M. Kitakaze, and P. Menasche, “Is adenosine preconditioning truly cardio-protective in coronary artery bypass surgery?” *The Annals of Thoracic Surgery*, vol. 70, pp. 590–594, 2000.

[93] T. Rinne, J. Laurikka, I. Penttilä, and S. Kaukinen, “Adenosine with cold blood cardioplegia during coronary revascularization,” *Journal of Cardiothoracic and Vascular Anesthesia*, vol. 14, no. 1, pp. 18–20, 2000.

[94] M. Wei, X. Wang, P. Kuukasjärvi et al., “Bradykinin preconditioning in coronary artery bypass grafting,” *Annals of Thoracic Surgery*, vol. 78, no. 2, pp. 492–497, 2004.

[95] C. G. Nebigil, N. Etienne, N. Messaddeq, and L. Maroteaux, “Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT1A receptor signaling,” *The FASEB Journal*, vol. 17, pp. 1373–1375, 2003.

[96] A. Bilir, N. Erkasap, T. Koken et al., “Effects of tramadol on myocardial ischaemia-reperfusion injury,” *Scandinavian Cardiovascular Journal*, vol. 41, pp. 242–247, 2007.

[97] P. Golino, F. Piscione, J. T. Willerson et al., “Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients,” *The New England Journal of Medicine*, vol. 324, pp. 641–648, 1991.

[98] M. Kitakaze, M. Asakura, J. Kim et al., “Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials,” *The Lancet*, vol. 370, no. 9597, pp. 1483–1493, 2007.

[99] J. Lønborg, N. Vejlstrup, H. Kelbæk et al., “Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction,” *European Heart Journal*, vol. 33, no. 12, pp. 1491–1499, 2012.

[100] J. A. Symons and P. S. Myles, “Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis,” *British Journal of Anaesthesia*, vol. 97, no. 2, pp. 127–136, 2006.

[101] P. Kružliak, O. Pechanova, and T. Kara, “New perspectives of nitric oxide donors in cardiac arrest and cardiopulmonary resuscitation treatment,” *Heart Failure Reviews*, vol. 19, no. 3, pp. 383–390, 2014.

[102] J. Sun, M. Morgan, R. E. Shen, C. Steenbergen, and E. Murphy, “Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport,” *Circulation Research*, vol. 101, no. 11, pp. 1155–1163, 2007.

[103] C. Piot, P. Croisille, P. Staat et al., “Effect of cyclosporine on reperfusion injury in acute myocardial infarction,” *The New England Journal of Medicine*, vol. 359, no. 5, pp. 473–481, 2008.

[104] D. J. Hausenloy, G. Kunst, E. Boston-Griffiths et al., “The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial,” *Heart*, vol. 100, pp. 544–549, 2014.

[105] D. Atar, J. L. Abitbol, H. Arheden et al., “Rationale and design of the “MITO CARE” Study: a phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRO40303 for the reduction of reperfusion injury in patients undergoing percutaneous coronary intervention for acute myocardial infarction,” *Cardiology*, vol. 123, no. 4, pp. 201–207, 2012.

[106] A. K. Chakrabarti, K. Feeney, C. Abueg et al., “Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial evaluate the safety, tolerability and on patients treated with standard therapy including stenting for elevation,” *American Heart Journal*, vol. 165, no. 4, pp. 509–514, 2013.

[107] Clinical Trials.gov. A service of the U.S. National Institutes of Health, Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack (RESUS-AMI) NCT01438086, http://clinicaltrials.gov/show/NCT01438086.

[108] Clinical Trials.gov. A service of the U.S. National Institutes of Health, Mangafodipir as an Adjunct to Percutaneous Coronary Intervention (MANAMI) NCT00966563, http://clinicaltrials.gov/ct2/show/NCT00966563.

[109] Clinical Trials.gov. A service of the U.S. National Institutes of Health, The Melatonin Adjunct in the Acute Myocardial Infarction Treated With Angioplasty (MARIA) NCT00640094, http://clinicaltrials.gov/ct2/show/NCT00640094.

[110] Clinical Trials.gov. A service of the U.S. National Institutes of Health, Effects of Nitric Oxide for Inhalation in Myocardial Infarction Size (NOMI) NCT01398384, http://clinicaltrials.gov/show/NCT01398384.

[111] Clinical Trials Government, “A service of the U.S. National Institutes of Health. Nitrites in Acute Myocardial Infarction (NOMI) NCT00640094, http://clinicaltrials.gov/ct2/show/NCT00640094.”
Infarction (NIAMI),” NCT01388504, http://clinicaltrials.gov/ct2/show/NCT01388504.

[112] D. A. Jones, M. Andiapan, T. J. A. van-Eijl et al., “The safety and efficacy of intracoronary nitrite infusion during acute myocardial infarction (NITRITE-AMI): study protocol of a randomised controlled trial,” BMJ Open, vol. 3, no. 4, Article ID e002813, 2013.

[113] Clinical Trials government. A service of the U.S. National Institutes of Health, “A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction,” http://clinicaltrials.gov/ct2/show/NCT01311518?term=thymosin+4+beta&rank=1.

[114] Clinical Trials gov. A service of the U.S. National Institutes of Health, Effect of METOprolol in CARDIoprotection During an Acute Myocardial Infarction. The METOCARD-CNIC Trial NCT01311700, http://clinicaltrials.gov/ct2/show/NCT01311700?term=mectocard&rank=1.

[115] B. R. Chaitman, “A review of the GUARDIAN trial results: Clinical implications and the significance of elevated perioperative CK-MB on 6-month survival,” Journal of Cardiac Surgery, vol. 18, no. 1, pp. 13–20, 2003.

[116] R. M. Mentzer Jr., C. Bartels, R. Bolli et al., “Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study,” Annals of Thoracic Surgery, vol. 85, no. 4, pp. 1261–1270, 2008.

[117] M. F. Newman, T. B. Ferguson, J. A. White et al., “Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial,” Journal of the American Medical Association, vol. 308, no. 2, pp. 157–164, 2012.

[118] P. K. Smith, S. K. Shernan, J. C. Chen et al., “Effects of CS complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG i and II trials,” Journal of Thoracic and Cardiovascular Surgery, vol. 142, no. 1, pp. 89–98, 2011.

[119] The Emip-FR Group, “Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project—Free Radicals,” European Heart Journal, vol. 21, no. 18, pp. 1537–1546, 2000.

[120] U. Zeymer, H. Suryapranata, J. P. Monassier et al., “The Na+/H+ exchange inhibitor enporide as an adjunct to early reperfusion therapy for acute myocardial infarction: results of the evaluation of the safety and cardioprotective effects of enporide in acute myocardial infarction (ESCAMI) trial,” Journal of the American College of Cardiology, vol. 38, no. 6, pp. 1644–1650, 2001.

[121] A. M. Lincoff, M. Roe, P. Aylward et al., “Inhibition of delta-protein kinase C by delcaserib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI randomized controlled trial,” European Heart Journal, 2014.

[122] F. D. Eefting, M. J. Cramer, P. R. S. Stella, B. J. Rensing, and P. A. Doevendans, “Rationale of the REPARATOR study: a randomised trial with serial cardiac MRI follow-up testing the ability of atorvastatin to reduce reperfusion damage after primary PCI for acute MI,” Netherlands Heart Journal, vol. 14, no. 3, pp. 95–98, 2006.

[123] D. M. Fatovich, D. A. Prentice, and G. J. Dobb, “Magnesium in cardiac arrest (the magic trial),” Resuscitation, vol. 35, pp. 237–241, 1997.

[124] S. R. Mehta, S. Yusuf, R. Diaz et al., “Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the controlled trial,” The Journal of the American Medical Association, vol. 293, pp. 437–446, 2005.

[125] S. S. Najjar, S. V. Rao, C. Melloni et al., “Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial,” JAMA, vol. 305, no. 18, pp. 1863–1872, 2011.

[126] I. Ott, S. Schulz, J. Mehilli et al., “Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial,” Circulation: Cardiovascular Interventions, vol. 5, pp. 408–413, 2010.

[127] D. Atar, P. Petzelbauer, J. Schwitter et al., “Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. results of the F.I.R.E. (efficacy of FX06 in the prevention of myocardial reperfusion injury trial)” Journal of the American College of Cardiology, vol. 53, no. 8, pp. 720–729, 2009.

[128] G. Heusch, “Cardioprotection: chances and challenges of its translation to the clinic,” The Lancet, vol. 381, no. 9861, pp. 166–175, 2013.

[129] H. Takahama, T. Minamino, H. Asanuma et al., “Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats,” Journal of the American College of Cardiology, vol. 53, no. 8, pp. 709–717, 2009.

[130] R. Bolli, L. Becker, G. Gross, R. Mentzer Jr., D. Balshaw, and D. A. Lathrop, “Myocardial protection at a crossroads: the need for translation into clinical therapy,” Circulation Research, vol. 95, no. 2, pp. 125–134, 2004.

[131] A. M. Ross, R. J. Gibbons, G. W. Stone, R. A. Kloner, and R. W. Alexander, “A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II),” Journal of the American College of Cardiology, vol. 45, no. 11, pp. 1775–1780, 2005.

[132] L. Schwartz Longacre, R. A. Kloner, A. E. Arai et al., “New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop,” Circulation, vol. 124, no. 10, pp. 1172–1179, 2011.

[133] D. J. Lefer and R. Bolli, “Development of an NIH Consortium for preclinical assessment of cardiac protective therapies (CAE-SAR): a paradigm shift in studies of infarct size limitation,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 16, no. 3–4, pp. 332–339, 2011.

[134] D. J. Haasenloy, H. Erik Botker, G. Condorelli et al., “Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology,” Cardiovascular Research, vol. 98, no. 1, pp. 7–27, 2013.